## David Hessl

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12151153/publications.pdf

Version: 2024-02-01

		87888	1	38484	
59	5,850	38		58	
papers	citations	h-index		g-index	
59	59	59		3802	
all docs	docs citations	times ranked		citing authors	

#	Article	IF	CITATIONS
1	Emergence of Developmental Delay in Infants and Toddlers With an $\langle i \rangle$ FMR1 $\langle i \rangle$ Mutation. Pediatrics, 2021, 147, .	2.1	16
2	Fragile X syndrome: an overview of cause, characteristics, assessment and management. Paediatrics and Child Health (United Kingdom), 2020, 30, 400-403.	0.4	12
3	Response to Placebo in Fragile X Syndrome Clinical Trials: An Initial Analysis. Brain Sciences, 2020, 10, 629.	2.3	21
4	Validation of the NIH Toolbox Cognitive Battery in intellectual disability. Neurology, 2020, 94, e1229-e1240.	1.1	44
5	Effects of mavoglurant on visual attention and pupil reactivity while viewing photographs of faces in Fragile X Syndrome. PLoS ONE, 2019, 14, e0209984.	2.5	22
6	Executive Function in Fragile X Syndrome: A Systematic Review. Brain Sciences, 2019, 9, 15.	2.3	31
7	Cognitive training for children and adolescents with fragile X syndrome: a randomized controlled trial of Cogmed. Journal of Neurodevelopmental Disorders, 2019, 11, 4.	3.1	23
8	Voice of People with Fragile X Syndrome and Their Families: Reports from a Survey on Treatment Priorities. Brain Sciences, 2019, 9, 18.	2.3	30
9	Association between IQ and FMR1 protein (FMRP) across the spectrum of CGG repeat expansions. PLoS ONE, 2019, 14, e0226811.	2.5	52
10	Extending the Parent-Delivered Early Start Denver Model to Young Children with Fragile X Syndrome. Journal of Autism and Developmental Disorders, 2019, 49, 1250-1266.	2.7	27
11	Standardized Assessment Accommodations for Individuals with Intellectual Disability. Contemporary School Psychology, 2018, 22, 443-457.	1.3	19
12	Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results. Neuropsychopharmacology, 2018, 43, 503-512.	5.4	102
13	Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome. Nature Reviews Drug Discovery, 2018, 17, 280-299.	46.4	247
14	Best Practices in Fragile X Syndrome Treatment Development. Brain Sciences, 2018, 8, 224.	2.3	37
15	Clinical and molecular correlates in fragile X premutation females. ENeurologicalSci, 2017, 7, 49-56.	1.3	13
16	Fragile X targeted pharmacotherapy: lessons learned and future directions. Journal of Neurodevelopmental Disorders, 2017, 9, 7.	3.1	99
17	Updated report on tools to measure outcomes of clinical trials in fragile X syndrome. Journal of Neurodevelopmental Disorders, 2017, 9, 14.	3.1	123
18	A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome. Journal of Neurodevelopmental Disorders, 2017, 9, 26.	3.1	67

#	Article	IF	Citations
19	Fragile X-associated tremor/ataxia syndrome: another phenotype of the fragile X gene. Clinical Neuropsychologist, 2016, 30, 810-814.	2.3	7
20	Psychiatric disorders among women with the fragile X premutation without children affected by fragile X syndrome. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2016, 171, 1139-1147.	1.7	21
21	The NIH Toolbox Cognitive Battery for intellectual disabilities: three preliminary studies and future directions. Journal of Neurodevelopmental Disorders, 2016, 8, 35.	3.1	96
22	A Randomized, Double-Blind, Placebo-Controlled Trial of Low-Dose Sertraline in Young Children With Fragile X Syndrome. Journal of Developmental and Behavioral Pediatrics, 2016, 37, 619-628.	1.1	65
23	Psychophysiological Responses to Emotional Stimuli in Children and Adolescents with Autism and Fragile X Syndrome. Journal of Clinical Child and Adolescent Psychology, 2015, 44, 250-263.	3.4	37
24	Anxiety disorders in fragile X premutation carriers: Preliminary characterization of probands and non-probands. Intractable and Rare Diseases Research, 2015, 4, 123-130.	0.9	39
25	Anxiety, attention problems, hyperactivity, and the Aberrant Behavior Checklist in fragile X syndrome. American Journal of Medical Genetics, Part A, 2014, 164, 141-155.	1.2	48
26	Improving IQ measurement in intellectual disabilities using true deviation from population norms. Journal of Neurodevelopmental Disorders, 2014, 6, 16.	3.1	111
27	Fear-Specific Amygdala Function in Children and Adolescents on the Fragile X Spectrum: A Dosage Response of the FMR1 Gene. Cerebral Cortex, 2014, 24, 600-613.	2.9	30
28	Feasibility, Reproducibility, and Clinical Validity of the Pediatric Anxiety Rating Scale—Revised for Fragile X Syndrome. American Journal on Intellectual and Developmental Disabilities, 2014, 119, 1-16.	1.6	14
29	Emotion Potentiated Startle in Fragile X Syndrome. Journal of Autism and Developmental Disorders, 2014, 44, 2536-2546.	2.7	7
30	A Randomized Double-Blind, Placebo-Controlled Trial of Minocycline in Children and Adolescents with Fragile X Syndrome. Journal of Developmental and Behavioral Pediatrics, 2013, 34, 147-155.	1.1	212
31	Outcome Measures for Clinical Trials in Fragile X Syndrome. Journal of Developmental and Behavioral Pediatrics, 2013, 34, 508-522.	1.1	136
32	Effects of STX209 (Arbaclofen) on Neurobehavioral Function in Children and Adults with Fragile X Syndrome: A Randomized, Controlled, Phase 2 Trial. Science Translational Medicine, 2012, 4, 152ra127.	12.4	289
33	Feasibility, reliability, and clinical validity of the Test of Attentional Performance for Children (KiTAP) in Fragile X syndrome (FXS). Journal of Neurodevelopmental Disorders, 2012, 4, 2.	3.1	47
34	Psychometric Study of the Aberrant Behavior Checklist in Fragile X Syndrome and Implications for Targeted Treatment. Journal of Autism and Developmental Disorders, 2012, 42, 1377-1392.	2.7	148
35	Increased prevalence of seizures in boys who were probands with the FMR1 premutation and co-morbid autism spectrum disorder. Human Genetics, 2012, 131, 581-589.	3.8	108
36	Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: prevalence and characterization. Journal of Neurodevelopmental Disorders, 2011, 3, 57-67.	3.1	269

#	Article	IF	CITATIONS
37	Aging in fragile X syndrome. Journal of Neurodevelopmental Disorders, 2010, 2, 70-76.	3.1	59
38	Advances in the Treatment of Fragile X Syndrome. Pediatrics, 2009, 123, 378-390.	2.1	513
39	Brief Report: Visual Processing of Faces in Individuals with Fragile X Syndrome: An Eye Tracking Study. Journal of Autism and Developmental Disorders, 2009, 39, 946-952.	2.7	73
40	A solution to limitations of cognitive testing in children with intellectual disabilities: the case of fragile X syndrome. Journal of Neurodevelopmental Disorders, 2009, 1, 33-45.	3.1	156
41	Broad Clinical Involvement in a Family Affected by the Fragile X Premutation. Journal of Developmental and Behavioral Pediatrics, 2009, 30, 544-551.	1.1	27
42	A Review of Fragile X Premutation Disorders. Journal of Clinical Psychiatry, 2009, 70, e1-e11.	2.2	119
43	Brief Report: Aggression and Stereotypic Behavior in Males with Fragile X Syndrome—Moderating Secondary Genes in a "Single Gene―Disorder. Journal of Autism and Developmental Disorders, 2008, 38, 184-189.	2.7	89
44	Secondary medical diagnosis in fragile X syndrome with and without autism spectrum disorder. American Journal of Medical Genetics, Part A, 2008, 146A, 1911-1916.	1.2	68
45	Autism Profiles of Males With Fragile X Syndrome. American Journal on Intellectual and Developmental Disabilites, 2008, 113, 427-438.	2.4	357
46	Early Acceleration of Head Circumference in Children with Fragile X Syndrome and Autism. Journal of Developmental and Behavioral Pediatrics, 2007, 28, 31-35.	1.1	56
47	Recommendations from Multi-disciplinary Focus Groups on Cascade Testing and Genetic Counseling for Fragile X-associated Disorders. Journal of Genetic Counseling, 2007, 16, 593-606.	1.6	70
48	Molecular and cognitive predictors of the continuum of autistic behaviours in fragile X. Neuroscience and Biobehavioral Reviews, 2007, 31, 315-326.	6.1	130
49	Autism Spectrum Disorders and Attention-Deficit/Hyperactivity Disorder in Boys with the Fragile X Premutation. Journal of Developmental and Behavioral Pediatrics, 2006, 27, S137-S144.	1.1	292
50	Social behavior and cortisol reactivity in children with fragile X syndrome. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2006, 47, 602-610.	5.2	111
51	Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 139B, 115-121.	1.7	215
52	The neuroanatomy and neuroendocrinology of fragile X syndrome. Mental Retardation and Developmental Disabilities Research Reviews, 2004, 10, 17-24.	3.6	137
53	Biological and environmental contributions to adaptive behavior in fragile X syndrome. American Journal of Medical Genetics Part A, 2003, 117A, 21-29.	2.4	57
54	Preschool Outcomes of Children of Depressed Mothers: Role of Maternal Behavior, Contextual Risk, and Children's Brain Activity. Child Development, 2003, 74, 1158-1175.	3.0	202

## DAVID HESSL

#	Article	IF	CITATION
55	Genetic and Environmental Influences on the Cognitive Outcomes of Children With Fragile X Syndrome. Journal of the American Academy of Child and Adolescent Psychiatry, 2002, 41, 237-244.	0.5	88
56	Autonomic and brain electrical activity in securely- and insecurely-attached infants of depressed mothers., 2001, 24, 135-149.		57
57	Infants of Depressed Mothers Exhibit Atypical Frontal Electrical Brain Activity during Interactions with Mother and with a Familiar, Nondepressed Adult. Child Development, 1999, 70, 1058-1066.	3.0	156
58	Frontal brain electrical activity in infants of depressed and nondepressed mothers: Relation to variations in infant behavior. Development and Psychopathology, 1999, 11, 589-605.	2.3	70
59	Social influences on early developing biological and behavioral systems related to risk for affective disorder. Development and Psychopathology, 1994, 6, 759-779.	2.3	79